COCHISE
Phase 2 Terminated
18 enrolled 9 charts
Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer
Phase 3 Terminated
340 enrolled
Study of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or Irinotecan as First Course of Treatment for Patients With Colorectal Cancer That Has Spread Beyond the Colon
Phase 2 Terminated
7 enrolled 5 charts
Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase NA Terminated
3 enrolled 8 charts
MRI in Predicting Response in Patients Receiving Combination Chemotherapy and Bevacizumab For Advanced or Metastatic Colorectal Cancer
Phase 2 Terminated
5 enrolled
FluoHeart
Phase 2 Terminated
20 enrolled
FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum
Phase 3 Terminated
238 enrolled
A Phase 1-2 Trial of Cetuximab in Combination With Oxaliplatin, Capecitabine, and Radiation Therapy Followed by Surgery for Locally-advanced Rectal Cancer
Phase 1/2 Terminated
23 enrolled 18 charts
Combination Chemotherapy Plus Bevacizumab With or Without Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer
Phase 3 Terminated
32 enrolled 14 charts
Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A)
Phase 2 Terminated
65 enrolled 8 charts
Gemcitabine and Oxaliplatin as Second-Line Therapy in Treating Patients With Metastatic Colon Cancer
Phase 2 Terminated
10 enrolled 7 charts
Combination Chemotherapy and Bevacizumab Before Surgery and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer
Phase 2 Terminated
1 enrolled 2 charts
BEBYP
Phase 3 Terminated
184 enrolled
High-Dose Cholecalciferol in Treating Patients Receiving Combination Chemotherapy and Bevacizumab as First-Line Therapy For Metastatic Colorectal Cancer
Phase 2 Terminated
10 enrolled 6 charts
Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors
Phase 1 Terminated
16 enrolled
Oxaliplatin and Capecitabine With or Without an Hepatic Arterial Infusion With Floxuridine in Treating Patients Who Are Undergoing Surgery and/or Ablation for Liver Metastases Due to Colorectal Cancer
Phase 3 Terminated
22 enrolled 3 charts
Combination Chemotherapy Plus Trastuzumab in Treating Patients With Advanced, Recurrent, or Metastatic Colorectal Cancer
Phase 2 Terminated
26 enrolled
Capecitabine, Oxaliplatin, and Gefitinib in Treating Patients With Metastatic Colorectal Cancer
Phase 1/2 Terminated
10 enrolled
Combination Chemotherapy and Bevacizumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Colorectal Cancer
Phase 3 Terminated
2,200 enrolled
Neoadjuvant and Adjuvant Capecitabine and Oxaliplatin in Treating Patients With Resectable Liver Metastases Secondary to Colorectal Cancer
Phase 2 Terminated
80 enrolled
Chemotherapy and Bevacizumab With or Without Radiofrequency Ablation in Treating Unresectable Liver Metastases in Patients With Colorectal Cancer
Phase 2 Terminated
119 enrolled
Dose Dense Therapy and Bevacizumab in Solid Tumors and Colorectal Cancer
Phase 1 Terminated
12 enrolled
Treatment of a Cancerous Disease of the Peritoneum With Complete Cytoreductive Surgery and Intraperitoneal Chemohyperthermia
Phase 2 Terminated
100 enrolled